Please login to the form below
Aragon Pharma
This page shows the latest Aragon Pharma news and features for those working in and with pharma, biotech and healthcare.
J&J’s Erleada first US drug for non-metastatic prostate cancer
J&J acquired Erleada when it took over Aragon Pharma in 2013 in a deal valued at $1bn.
Latest news
-
J&J completes Aragon deal as Seragon is born
The deal secures a promising new prostate cancer therapy for the pharma major in the form of Aragon's ARN-509, a second generation androgen receptor signalling inhibitor which has reached ... Seragon spun out. The closure of the deal also sees the
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Novavax gets $1.6bn from US government for coronavirus vaccine
- Communiqué Awards 2020: Results - Communiqué Awards
- FDA approves Roche’s Actemra COVID-19 trial
- Communiqué Awards 2020: Results - Communiqué Awards
- Mesoblast expands compassionate use COVID-19 programme
- Regeneron’s COVID-19 antibody cocktail enters phase 3 trial
- Intelligence that redefines success
- IFPMA launches AMR Action Fund to tackle antimicrobial resistance
- Merck expands partnership with Zymeworks for multispecific antibodies
- Novartis reveals full phase 3 results for Enerzair Breezhaler
- Artificial Intelligence in Digital Therapeutics
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
PMHub
mXm Medical Communications
mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...
Latest intelligence
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
- From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
- Multichannel engagement and the need for greater understanding of European markets
- By Laurence Olding and Georgina James...
- A snapshot of… Exscientia
- ...
Quick links
Infographics
